Page 29 - Read Online

dose specification and target delineation for postoperative radiotherapy Brachytherapy 2010;9:227-34.
for oral cavity cancer. Head Neck 2015;37:933-9. 25. Oota S, Shibuya H, Yoshimura R, Watanabe H, Miura M. Brachytherapy of
5. Leclerc M, Lartigau E, Lacornerie T, Daisne JF, Kramar A, Grégoire V. Primary stage II mobile tongue carcinoma. Prediction of local control and QOL.
tumor delineation based on (18)FDG PET for locally advanced head and neck Radiat Oncol 2006;1:21.
cancer treated by chemo-radiotherapy. Radiother Oncol 2015;116:87-93. 26. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H,
6. Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Matsuura K, Ito K. Interstitial brachytherapy for stage I and II squamous
Herk M, Lee A, Maingon P, Nutting C, O’Sullivan B, Porceddu SV, Rosenthal cell carcinoma of the oral tongue: factors influencing local control and soft
DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in tissue complications. Int J Radiat Oncol Biol Phys 1999;44:767-75.
the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, 27. Bachaud JM, Delannes M, Allouache N, Benchalal M, Alzieu C, David JM,
NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Serrano E, Daly-Schveitzer NJ. Radiotherapy of stage I and II carcinomas of
Radiother Oncol 2015;117:83-90. the mobile tongue and/or floor of the mouth. Radiother Oncol 1994;31:199-
7. Chao KSC, Mohan R, Marinetti TD, Dong L. Intensity-Modulated Radiation 206.
Treatment Techniques and Clinical Applications. In: Halperin EC, Wazer DE, 28. Inoue T, Inoue T, Yoshida K, Yoshioka Y, Shimamoto S, Tanaka E, Yamazaki H,
Perez CA, Brady LW, editors. Perez and Brady’s Principles and Practice of Shimizutani K, Teshima T, Furukawa S. Phase III trial of high- vs. low-dose-
Radiation Oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; rate interstitial radiotherapy for early mobile tongue cancer. Int J Radiat
2013. p. 221-45. Oncol Biol Phys 2001;51:171-5.
8. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological 29. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N,
basis and clinical results of the simultaneous integrated boost (SIB) Shimizutani K, Inoue T. Brachytherapy for early oral tongue cancer: low
intensity modulated radiotherapy (IMRT) for head and neck cancer: a dose rate to high dose rate. J Radiat Res 2003;44:37-40.
review. Crit Rev Oncol Hematol 2010;73:111-25. 30. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N,
9. Marta GN, Silva V, de Andrade Carvalho H, de Arruda FF, Hanna SA, Gadia Shimizutani K. Comparison of three major radioactive sources for
R, da Silva JL, Correa SF, Vita Abreu CE, Riera R. Intensity-modulated brachytherapy used in the treatment of node negative T1-T3 oral tongue
radiation therapy for head and neck cancer: systematic review and meta- cancer: influence of age on outcome. Anticancer Res 2007;27:491-7.
analysis. Radiother Oncol 2014;110:9-15. 31. Ihara N, Shibuya H, Yoshimura R, Oota S, Miura M, Watanabe H. Interstitial
10. Beadle BM, Liao KP, Elting LS, Buchholz TA, Ang KK, Garden AS, Guadagnolo brachytherapy and neck dissection for Stage III squamous cell carcinoma
BA. Improved survival using intensity-modulated radiation therapy in head of the mobile tongue. Acta Oncol 2005;44:709-16.
and neck cancers: a SEER-Medicare analysis. Cancer 2014;120:702-10. 32. Kakimoto N, Inoue T, Inoue T, Murakami S, Furukawa S, Yoshida K, Yoshioka
11. Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács G, Levendag P, Peiffert D, Polo Y, Yamazaki H, Tanaka E, Shimizutani K. Results of low- and high-dose-rate
A, Rovirosa A, Strnad V. GEC-ESTRO recommendations for brachytherapy interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol
for head and neck squamous cell carcinomas. Radiother Oncol 2009;91:150-6. 2003;68:123-8.
12. Lau HY, Hay JH, Flores AD, Threlfall WJ. Seven fractions of twice daily 33. Akiyama H, Yoshida K, Shimizutani K, Yamazaki H, Koizumi M, Yoshioka
high dose-rate brachytherapy for node-negative carcinoma of the mobile Y, Kakimoto N, Murakami S, Furukawa S, Ogawa K. Dose reduction trial
tongue results in loss of therapeutic ratio. Radiother Oncol 1996;39:15-8. from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-
13. Liu Z, Huang S, Zhang D. High dose rate versus low dose rate brachytherapy rate interstitial brachytherapy for early oral tongue cancer. J Radiat Res
for oral cancer--a meta-analysis of clinical trials. PLoS One 2013;8:e65423. 2012;53:722-6.
14. Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B; American 34. Donath D, Vuong T, Shenouda G, MacDonald B, Tabah R. The potential uses
Brachytherapy Society. The American Brachytherapy Society of high-dose-rate brachytherapy in patients with head and neck cancer. Eur
recommendations for high-dose-rate brachytherapy for head-and-neck Arch Otorhinolaryngol 1995;252:321-4.
carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1190-8. 35. Inoue T, Inoue T, Yamazaki H, Koizumi M, Kagawa K, Yoshida K, Shiomi H,
15. Petera J, Matula P, Paluska P, Sirak I, Macingova Z, Kasaova L, Frgala T, Imai A, Shimizutani K, Tanaka E, Nose T, Teshima T, Furukawa S, Fuchihata H.
Hodek M, Vosmik M. High dose rate versus low dose rate brachytherapy High dose rate versus LDR interstitial radiotherapy for carcinoma of the
in the treatment of tongue carcinoma - a radiobiological study. Neoplasma floor of mouth. Int J Radiat Oncol Biol Phys 1998;41:53-8.
2009;56:163-8. 36. Matsumoto K, Sasaki T, Shioyama Y, Nakamura K, Atsumi K, Nonoshita T,
16. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N, Ooga S, Yoshitake T, Uehara S, Hirata H, Honda H. Treatment outcome of
Shimizutani K, Inoue T. Brachytherapy for early oral tongue cancer: low high-dose-rate interstitial radiation therapy for patients with stage I and II
dose rate to high dose rate. J Radiat Res 2003;44:37-40. mobile tongue cancer. Jpn J Clin Oncol 2013;43:1012-7.
17. Van Limbergen E, Joiner M, Van der Kogel A, Dörr W. Radiobiology of LDR, 37. Khalilur R, Hayashi K, Shibuya H. Brachytherapy for tongue cancer in
HDR, PDR and VLDR Brachytherapy. In: Van Limbergen E, Pötter R, Hoskin the very elderly is an alternative to external beam radiation. Br J Radiol
P, Baltas D, editors. The GEC ESTRO Handbook of Brachytherapy. 2nd ed 2011;84:747-9.
(ebook version 1 12/11/2015). Available from: http://www.estro.org/search 38. Vedasoundaram P, Prasanna AK, Ks R, Selvarajan G, Sinnatamby M,
?type=Activities&q=radiobiology+ldr+hdr&alloptions=on. Ramapandian S, Kandasamy S. Role of high dose rate interstitial
18. Grégoire V, Coche E, Cosnard G, Hamoir M, Reychler H. Selection and brachytherapy in early and locally advanced squamous cell carcinoma of
delineation of lymph node target volumes in head and neck conformal buccal mucosa. Springerplus 2014;3:590.
radiotherapy. Proposal for standardizing terminology and procedure based 39. Lee SU, Cho KH, Moon SH, Choi SW, Park JY, Yun T, Lee SH, Lim YK,
on the surgical experience. Radiother Oncol 2000;56:135-50. Jeong CY. Clinical outcome of high-dose-rate interstitial brachytherapy in
19. Huang SH, Hwang D, Lockwood G, Goldstein DP, O’Sullivan B. Predictive patients with oral cavity cancer. Radiat Oncol J 2014;32:238-46.
value of tumor thickness for cervical lymph-node involvement in squamous 40. Tuček L, Petera J, Sirák I, Vošmik M, Doležalová H, Brokešová S, Hodek M,
cell carcinoma of the oral cavity: A meta-analysis of reported studies. Kašaová L, Paluska P. Hyperfractionated high-dose rate brachytherapy in the
Cancer 2009;15:1489-97. treatment of oral tongue cancer. Rep Pract Oncol Radiother 2011;16:243-7.
20. Sresty NV, Ramanjappa T, Raju AK, Muralidhar KR, Sudarshan G. Acquisition 41. Pernot M, Hoffstetter S, Peiffert D, Aletti P, Lapeyre M, Marchal C, Luporsi E,
of equal or better planning results with interstitial brachytherapy when Bey P, Nancy VL. Role of interstitial brachytherapy in oral and oropharyngeal
compared with intensity-modulated radiotherapy in tongue cancers. carcinoma: reflection of a series of 1344 patients treated at the time of initial
Brachytherapy 2010;9:235-8. presentation. Otholaryngol Head Neck Surg 1996;115:519-26.
21. Studer G, Brown M, Bredell M, Graetz KW, Huber G, Linsenmeier C, Najafi 42. Lefebvre JL, Coche-Dequeant B, Buisset E, Mirabel X, Van JT, Prevost B.
Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in Management of early oral cavity cancer. Experience of Centre Oscar
oral cavity cancer: update. Radiat Oncol 2012;7:84. Lambret. Eur J Cancer B Oral Oncol 1994;30B:216-20.
22. Leung TW, Wong VY, Kwan KH, Ng TY, Wong CM, Tung SY, Leung LC, O 43. Mazeron JJ, Simon JM, Le Péchoux C, Crook JM, Grimard L, Piedbois
SK. High dose rate brachytherapy for early stage oral tongue cancer. Head P, Le Bourgeois JP, Pierquin B. Effect of dose rate on local control and
Neck 2002;24:274-81. complications in definitive irradiation of T1-2 squamous cell carcinomas of
23. Martínez-Monge R, Gómez-Iturriaga A, Cambeiro M, Garrán C, mobile tongue and floor of mouth with interstitial iridium-192. Radiother
Montesdeoca N, Aristu JJ, Alcalde J. Phase I-II trial of perioperative Oncol 1991;21:39-47.
high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. 44. Marsiglia H, Haie-Meder C, Sasso G, Mamelle G, Gerbaulet A.
Brachytherapy 2009;8:26-33. Brachytherapy for T1-T2 floor of mouth cancers: the Gustave-Roussy
24. Guinot JL, Santos M, Tortajada MI, Carrascosa M, Estellés E, Vendrell Institute experience. Int J Radiat Oncol Biol Phys 2002;52:1257-63.
JB, Muelas R, Chust ML, Mengual JL, Arribas L. Efficacy of high-dose- 45. Dearnaley DP, Dardoufas C, A’Hearn RP, Henk JM. Interstitial irradiation
rate interstitial brachytherapy in patients with oral tongue carcinoma. for carcinoma of the tongue and floor of mouth: royal marsden hospital
164 Plast Aesthet Res || Volume 3 || May 25, 2016